Forebyggelse af respiratorisk syncytialvirus-infektion hos spædbørn

Sidse Vang Braa Andersen; Lisbeth Samsø Schmidt; Ulla Birgitte Hartling; Anne Cathrine F. Viuff; Mette Holm; Lone Graff Stensballe; Marie Louise Von Linstow

doi:10.61409/V11250898

Forebyggelse af respiratorisk syncytialvirus-infektion hos spædbørn

Sidse Vang Braa Andersen
, Lisbeth Samsø Schmidt
, Ulla Birgitte Hartling
, Anne Cathrine F. Viuff
, Mette Holm
, Lone Graff Stensballe
, Marie Louise Von Linstow^*

^*Kontaktforfatter

KI, OUH, Forskningsenhed for Pædiatri (Odense)

Københavns Universitet
Herlev Hospital
Aarhus Universitetshospital
Rigshospitalet

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › peer review

4 Downloads (Pure)

Abstract

Respiratory syncytial virus (RSV) is the leading cause of infant hospitalisations in Denmark, with about 1,300 admissions annually. Until now, prevention relied on palivizumab for high-risk infants, limited by high costs and monthly injections. This review describes new preventive options including maternal vaccination (Abrysvo) and monoclonal antibodies (nirsevimab, clesrovimab). From October 2025, Denmark introduced a seasonal maternal vaccination, expected to substantially reduce RSV-related hospitalisations. Additionally, monoclonal antibodies are recommended for premature and high-risk infants.

Bidragets oversatte titel	Prevention of respiratory syncytial virus in children
Originalsprog	Dansk
Artikelnummer	V11250898
Tidsskrift	Ugeskrift for Læger
Vol/bind	188
Udgave nummer	11
ISSN	0041-5782
DOI	https://doi.org/10.61409/V11250898
Status	Udgivet - 25. maj 2026

Dokumenter og links

10.61409/V11250898Licens: CC BY-NC-ND

Open Access VersionForlagets udgivne version, 615 KBLicens: CC BY-NC-ND

SDU link

Tjek adgangen til materialet i Syddansk Universitetsbiblioteks søgemaskine

Citationsformater

@article{10f1ed1efd8f462f9b7de233ba29ba97,

title = "Forebyggelse af respiratorisk syncytialvirus-infektion hos sp{\ae}db{\o}rn",

abstract = "Respiratory syncytial virus (RSV) is the leading cause of infant hospitalisations in Denmark, with about 1,300 admissions annually. Until now, prevention relied on palivizumab for high-risk infants, limited by high costs and monthly injections. This review describes new preventive options including maternal vaccination (Abrysvo) and monoclonal antibodies (nirsevimab, clesrovimab). From October 2025, Denmark introduced a seasonal maternal vaccination, expected to substantially reduce RSV-related hospitalisations. Additionally, monoclonal antibodies are recommended for premature and high-risk infants.",

author = "\{Braa Andersen\}, \{Sidse Vang\} and Schmidt, \{Lisbeth Sams{\o}\} and Hartling, \{Ulla Birgitte\} and Viuff, \{Anne Cathrine F.\} and Mette Holm and Stensballe, \{Lone Graff\} and \{Von Linstow\}, \{Marie Louise\}",

year = "2026",

month = may,

day = "25",

doi = "10.61409/V11250898",

language = "Dansk",

volume = "188",

journal = "Ugeskrift for L{\ae}ger",

issn = "0041-5782",

publisher = "L{\ae}geforeningen",

number = "11",

}

TY - JOUR

T1 - Forebyggelse af respiratorisk syncytialvirus-infektion hos spædbørn

AU - Braa Andersen, Sidse Vang

AU - Schmidt, Lisbeth Samsø

AU - Hartling, Ulla Birgitte

AU - Viuff, Anne Cathrine F.

AU - Holm, Mette

AU - Stensballe, Lone Graff

AU - Von Linstow, Marie Louise

PY - 2026/5/25

Y1 - 2026/5/25

N2 - Respiratory syncytial virus (RSV) is the leading cause of infant hospitalisations in Denmark, with about 1,300 admissions annually. Until now, prevention relied on palivizumab for high-risk infants, limited by high costs and monthly injections. This review describes new preventive options including maternal vaccination (Abrysvo) and monoclonal antibodies (nirsevimab, clesrovimab). From October 2025, Denmark introduced a seasonal maternal vaccination, expected to substantially reduce RSV-related hospitalisations. Additionally, monoclonal antibodies are recommended for premature and high-risk infants.

AB - Respiratory syncytial virus (RSV) is the leading cause of infant hospitalisations in Denmark, with about 1,300 admissions annually. Until now, prevention relied on palivizumab for high-risk infants, limited by high costs and monthly injections. This review describes new preventive options including maternal vaccination (Abrysvo) and monoclonal antibodies (nirsevimab, clesrovimab). From October 2025, Denmark introduced a seasonal maternal vaccination, expected to substantially reduce RSV-related hospitalisations. Additionally, monoclonal antibodies are recommended for premature and high-risk infants.

U2 - 10.61409/V11250898

DO - 10.61409/V11250898

M3 - Tidsskriftartikel

C2 - 41738099

SN - 0041-5782

VL - 188

JO - Ugeskrift for Læger

JF - Ugeskrift for Læger

IS - 11

M1 - V11250898

ER -

Forebyggelse af respiratorisk syncytialvirus-infektion hos spædbørn

Abstract

Dokumenter og links

SDU link

Fingeraftryk

Citationsformater